Evidence map›Paper›PMID 21633324›Full record

ArticleJournal of visualized experiments : JoVE2011

Gene transfer for ischemic heart failure in a preclinical model.

Kiyotake Ishikawa, Dennis Ladage, Lisa Tilemann, Kenneth Fish, Yoshiaki Kawase, Roger J Hajjar

Open access · bronzeAbstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of visualized experiments : JoVE, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure.Molecular therapy : the journal of the American Society of Gene Therapy · 2014
    Article
  10. Characterizing preclinical models of ischemic heart failure: differences between LAD and LCx infarctions.American journal of physiology. Heart and circulatory physiology · 2014
    Article
  11. Percutaneous approaches for efficient cardiac gene delivery.Journal of cardiovascular translational research · 2013
    Review
  12. Article
  13. Article
  14. Article
  15. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.Molecular therapy : the journal of the American Society of Gene Therapy · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Kiyotake IshikawaCardiovascular Research Center, Mount Sinai School of Medicine.
Dennis Ladage
Lisa Tilemann
Kenneth Fish
Yoshiaki Kawase
Roger J Hajjar
Cardiovascular Research Center · BRIcahn School of Medicine at Mount Sinai · US

Funding

PICOT and Cardiac HypertrophyR01HL080498 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HAJJAR, ROGER J. · 2006 to 2010
$2.2M
Targeting Calcium Cycling in Pre-Clinical Model CardiacR01HL083156 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HAJJAR, ROGER J. · 2006 to 2010
$1.7M
C-TRIP: Targeted Gene Therapy for the Treatment of Heart Failure (P20)P20HL100396 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAJJAR, ROGER J. · 2010 to 2011
$1.7M
Gene Therapy with Cardiotropic Vectors for the Treatment of Heart FailureR01HL088434 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAJJAR, ROGER J. · 2010 to 2013
$1.7M
K and Ca Channels in Cardiac Hypertrophy and FailureR01HL071763 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HAJJAR, ROGER J. · 2003 to 2006
$1.6M
Regression of cardiac hypertrophyR01HL093183 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAJJAR, ROGER J. · 2009 to 2010
$1.1M
NHLBI NIH HHS HL071763NHLBI NIH HHS HL080498NHLBI NIH HHS HL083156NHLBI NIH HHS HL088434NHLBI NIH HHS P20 HL100396NHLBI NIH HHS P20HL100396NHLBI NIH HHS R01 HL071763NHLBI NIH HHS R01 HL080498NHLBI NIH HHS R01 HL083156NHLBI NIH HHS R01 HL088434NHLBI NIH HHS R01 HL093183
6 · The paper itself

Abstract

Various emerging technologies are being developed for patients with heart failure. Well-established preclinical evaluations are necessary to determine their efficacy and safety. Gene therapy using viral vectors is one of the most promising approaches for treating cardiac diseases. Viral delivery of various different genes by changing the carrier gene has immeasurable therapeutic potential. In this video, the full process of an animal model of heart failure creation followed by gene transfer is presented using a swine model. First, myocardial infarction is created by occluding the proximal left anterior descending coronary artery. Heart remodeling results in chronic heart failure. Unique to our model is a fairly large scar which truly reflects patients with severe heart failure who require aggressive therapy for positive outcomes. After myocardial infarct creation and development of scar tissue, an intracoronary injection of virus is demonstrated with simultaneous nitroglycerine infusion. Our injection method provides simple and efficient gene transfer with enhanced gene expression. This combination of a myocardial infarct swine model with intracoronary virus delivery has proven to be a consistent and reproducible methodology, which helps not only to test the effect of individual gene, but also compare the efficacy of many genes as therapeutic candidates.

Indexed as

Disease Models, AnimalGene Transfer TechniquesAdenoviridaeAnimalsFemaleHeart FailureMyocardial InfarctionMyocardial IschemiaSwine

Identifiers

PMID21633324
PMCPMC3197127
OpenAlexW1976981067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.